Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
About David Allan
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Related Photos
prev
next
-
Getty Images
YORK, ENGLAND - AUGUST 18: Barney McGrew (#4) ridden by Phillip Makin beats Hamish McGonagall (#7) ridden by David Allan to win the The Symphony Group Stakes during the Ebor Festival held at York Racecourse on August 18, 2009 in York, England.
View Photo » -
Getty Images
YORK, ENGLAND - AUGUST 18: Barney McGrew (#4) ridden by Phillip Makin beats Hamish McGonagall (#7) ridden by David Allan to win the The Symphony Group Stakes during the Ebor Festival held at York Racecourse on August 18, 2009 in York, England.
View Photo » -
Getty Images
YORK, ENGLAND - AUGUST 18: Barney McGrew (#4) ridden by Phillip Makin beats Hamish McGonagall (#7) ridden by David Allan to win the The Symphony Group Stakes during the Ebor Festival held at York Racecourse on August 18, 2009 in York, England.
View Photo » -
Getty Images
YORK, ENGLAND - AUGUST 18: Barney McGrew (#4) ridden by Phillip Makin beats Hamish McGonagall (#7) ridden by David Allan to win the The Symphony Group Stakes during the Ebor Festival held at York Racecourse on August 18, 2009 in York, England.
View Photo »
Getty Images
YORK, ENGLAND - AUGUST 18: Barney McGrew (#4) ridden by Phillip Makin beats Hamish McGonagall (#7) ridden by David Allan to win the The Symphony Group Stakes during the Ebor Festival held at York Racecourse on August 18, 2009 in York, England.
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/7
-
This is a new generation of rationally designed antibodies that bind to HER2/neu on cancer cells to an extent similar to that seen with trastuzumab (Herceptin(R), Genentech/Roche) but are distinguished from trastuzumab by their minimal targeting of HER2 on cardiac cells, which is expected to result in r...
-
I had three mentors ... My dad, Henry Cieszynski, who was an analyst for 40 years, taught me a lot. Peter Brown, the chairman of Canaccord Capital, where I worked for 10 years, was a big inspiration to me, and David Allan, who gave me my first job on Bay Street.
SOURCE: Toronto Star -
This is a new generation of rationally designed antibodies that bind to HER2/neu on cancer cells to an extent similar to that seen with trastuzumab (Herceptin(R), Genentech/Roche) but are distinguished from trastuzumab by their minimal targeting of HER2 on cardiac cells, which is expected to result in r...
-
These data are convincing evidence that nimotuzumab is an efficacious and safe drug and highlight its potential in the head and neck cancer indication. In this respect we note that the National Cancer Centre of Singapore has initiated a global Phase III trial with nimotuzumab in the adjuvant setting for...
-
Though challenging, this effort is requisite to achieving a full understanding of the current and future state of the lakes, and will be particularly valuable in the current era of rapidly expanding human impacts, including anthropogenic climate change
-
Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made...
-
Mexico is the 21st country to have approved nimotuzumab for marketing and, while YM's license for major market territories for nimotuzumab does not include Mexico, this approval reflects the growing recognition throughout much of the world of the value to patients of our drug and the progress being made...
– Related Conversations
There are no results for this module. Edit the module to change the search term used to query Twitter.